pre-IPO PHARMA

COMPANY OVERVIEW

Actym Therapeutics, Inc. is an immunotherapy company focused on the discovery and development of novel therapies that are intended to transform the treatment of cancer. Actym's STACT technology platform is designed to harness the body's natural immune system to modify the tumor microenvironment. STACT allows for targeting immune pathways that are intractable using conventional small molecule or antibody-based therapeutics.


LOCATION

  • Berkeley, CA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.actymthera.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Nov 7, 2022

    Actym Therapeutics Reports Preclinical Data Demonstrating ACTM-838's Ability to Generate Anti-Tumor Immunity


    May 12, 2022

    Actym Therapeutics Announces Significant Expansion of Senior Leadership


    Feb 28, 2022

    Actym Therapeutics and Wacker Biotech Sign Manufacturing Contract for Actym's Lead Candidate for the Treatment of Solid Tumors


    Feb 16, 2022

    Actym Therapeutics CEO Dr. Christopher Thanos named one of the "Top 25 Biotech CEOs of 2022"


    Feb 14, 2022

    Actym Therapeutics Announces Issuance of US Patent


    For More Press Releases


    Google Analytics Alternative